The annual International Association for the Protection of IP (AIPPI) conference in Helsinki, Finland, assessed the potential problems for pharmaceutical companies trying to brand their medicinal products.
During a workshop on September 6, one issue discussed was the difference between a trademark signifying a branded product and an international nonproprietary name (INN), which signifies a medical effect.
Examples of registered INNs include -olol for beta blockers (eg, atenolol) and -oxetine for fluoxetine derivatives, a group of antidepressants.
Raffaella Mattivelli, INN programme manager at the World Health Organization (WHO), said: “We have developed a resolution to ensure the INN is prominently displayed on the box of products and is easy to understand.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
AIPPI, pharmaceuticals, trademarks, brands, INN
